A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib)
on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary
fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this
study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period
during which they will reside at the clinical trial site.